Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.

Autor: Cheema PK; William Osler Health System, Brampton, ON L6R 3J7, Canada., Iafolla MAJ; William Osler Health System, Brampton, ON L6R 3J7, Canada., Abdel-Qadir H; Women's College Hospital Research Institute, Toronto, ON M5S 1B2, Canada.; Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON M5G 2N2, Canada., Bellini AB; William Osler Health System, Brampton, ON L6R 3J7, Canada., Chatur N; Division of Gastroenterology, Faculty of Medicine, Vancouver General Hospital (Sanders), University of British Columbia, Vancouver, BC V5Z 1M9, Canada., Chandok N; William Osler Health System, Brampton, ON L6R 3J7, Canada., Comondore VR; William Osler Health System, Brampton, ON L6R 3J7, Canada., Cunningham M; Toronto Centre for Liver Disease, University Health Network, Toronto, ON M5G 2C4, Canada., Halperin I; Division of Endocrinology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada., Hu AB; William Osler Health System, Brampton, ON L6R 3J7, Canada., Jaskolka D; William Osler Health System, Brampton, ON L6R 3J7, Canada., Darvish-Kazem S; William Osler Health System, Brampton, ON L6R 3J7, Canada., Khandaker MH; William Osler Health System, Brampton, ON L6R 3J7, Canada., Kitchlu A; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada., Sachdeva JS; William Osler Health System, Brampton, ON L6R 3J7, Canada., Shapera S; Department of Medicine, University of Toronto, Toronto, ON M5G 2N2, Canada., Woolnough NRJ; William Osler Health System, Brampton, ON L6R 3J7, Canada., Nematollahi M; William Osler Health System, Brampton, ON L6R 3J7, Canada.
Jazyk: angličtina
Zdroj: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Oct 18; Vol. 31 (10), pp. 6356-6383. Date of Electronic Publication: 2024 Oct 18.
DOI: 10.3390/curroncol31100473
Abstrakt: The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs). Delayed recognition without appropriate treatment can have serious and life-threatening consequences. The management of irAEs presents a unique set of challenges that must be addressed at a multidisciplinary level. Although various national and international guidelines and working groups provide high-level recommendations for the management of irAEs, practical guidance is lacking. Furthermore, timely collaboration between specialists requires institutional protocols that enable the early recognition, assessment, and treatment of irAEs. Such protocols should be developed by institution specialists and include algorithms for all healthcare providers involved in the care of patients treated with ICIs. At William Osler Health System in Brampton, Ontario, practical step-by-step multidisciplinary treatment approaches with recommendations for the management of irAEs were developed in collaboration with experts across Canada. Here, we provide an in-depth description of the approaches, outlining baseline investigations prior to the initiation of ICIs, as well as the monitoring and management of irAEs based on symptoms, severity, and involved organ systems. We encourage other centres to adapt and modify our approaches according to their specific needs and requirements.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje